ÂÜÀòÂÒÂ×

Wes joined Kronos Bio in 2020 as Vice President of Chemistry. His drug discovery experience spans a 20 year career at Merck & Co. at both the West Point, Pennsylvania and Boston sites. Wes and his teams have discovered and advanced into clinical development molecules addressing challenging oncology, immunology, cardiovascular, and neuroscience targets. Recent preclinical and clinical candidate molecules invented by Wes and his teams for oncology and immunology indications include orally dosed protein-protein interaction inhibitors, inhaled kinase inhibitors, nuclear hormone receptor antagonists, and intratumorally administered innate immune agonists. Wes earned his Ph.D. in synthetic organic chemistry at Harvard University under the direction of David Evans. He completed an M. Phil. in bio-organic chemistry at the University of Cambridge in the laboratory of Dudley Williams and received a B.S. in Chemistry from the University of North Carolina at Chapel Hill.